|
WO1998032869A1
(en)
*
|
1997-01-29 |
1998-07-30 |
Neurosearch A/S |
Expression vectors and methods for in vivo expression of therapeutic polypeptides
|
|
EP1319082B1
(en)
*
|
2000-09-18 |
2005-11-16 |
Genzyme Corporation |
Expression vectors containing hybrid ubiquitin promoters
|
|
EP1624067A3
(en)
*
|
2000-09-18 |
2006-03-15 |
Genzyme Corporation |
Expression vectors containing hybrid ubiquitin promoters
|
|
CA2812799C
(en)
*
|
2001-07-04 |
2016-01-26 |
Chromagenics B.V. |
Dna sequences comprising gene transcription regulatory qualities and methods for detecting and using such dna sequences
|
|
US7344886B2
(en)
*
|
2002-11-29 |
2008-03-18 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
Neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product
|
|
DE10256083A1
(de)
|
2002-11-29 |
2004-08-12 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Expressionsvektor, Verfahren zur Herstellung von heterologen Genprodukten und Selektionsverfahren für hochproduzierende rekombinante Zellen
|
|
US7384744B2
(en)
|
2002-11-29 |
2008-06-10 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
|
|
DE10338531A1
(de)
|
2003-08-19 |
2005-04-07 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Reklonierung von Produktionszellen
|
|
US8669109B2
(en)
|
2003-08-19 |
2014-03-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Methods of producing proteins in Chinese hamster ovary (CHO) cells
|
|
US20050101017A1
(en)
*
|
2003-11-10 |
2005-05-12 |
Wojtek Auerbach |
Method of improving gene targeting using a ubiquitin promoter
|
|
GB0509965D0
(en)
*
|
2005-05-17 |
2005-06-22 |
Ml Lab Plc |
Improved expression elements
|
|
CA2611946C
(en)
*
|
2005-06-20 |
2013-04-16 |
Cadila Healthcare Limited |
Expression vector and methods of producing high levels of proteins
|
|
EP1806365A1
(en)
|
2006-01-05 |
2007-07-11 |
Boehringer Ingelheim International GmbH |
Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
|
|
US20080124760A1
(en)
*
|
2006-07-26 |
2008-05-29 |
Barbara Enenkel |
Regulatory Nucleic Acid Elements
|
|
LT2771031T
(lt)
|
2011-10-28 |
2018-08-27 |
Prothena Biosciences Limited |
Humanizuoti antikūnai, kurie atpažįsta alfa sinukleiną
|
|
UA115439C2
(uk)
|
2012-01-27 |
2017-11-10 |
Протена Біосаєнсиз Лімітед |
Гуманізоване антитіло, яке розпізнає альфа-синуклеїн
|
|
UA118441C2
(uk)
|
2012-10-08 |
2019-01-25 |
Протена Біосаєнсиз Лімітед |
Антитіло, що розпізнає альфа-синуклеїн
|
|
WO2014102103A2
(en)
|
2012-12-31 |
2014-07-03 |
Boehringer Ingelheim International Gmbh |
Heterologous intron within a signal peptide
|
|
WO2014102101A1
(en)
|
2012-12-31 |
2014-07-03 |
Boehringer Ingelheim International Gmbh |
Novel intron sequences
|
|
JP6674888B2
(ja)
|
2013-03-13 |
2020-04-01 |
プロセナ バイオサイエンシーズ リミテッド |
タウ免疫療法
|
|
WO2014182972A2
(en)
|
2013-05-10 |
2014-11-13 |
The Regents Of The University Of California |
Diagnostic and monitoring system for huntington's disease
|
|
US10513555B2
(en)
|
2013-07-04 |
2019-12-24 |
Prothena Biosciences Limited |
Antibody formulations and methods
|
|
US9850302B2
(en)
|
2013-07-12 |
2017-12-26 |
Prothena Biosciences Limited |
Antibodies that recognize IAPP
|
|
US9951131B2
(en)
|
2013-07-12 |
2018-04-24 |
Prothena Biosciences Limited |
Antibodies that recognize IAPP
|
|
US11191832B2
(en)
|
2013-11-19 |
2021-12-07 |
Prothena Biosciences Limited |
Monitoring immunotherapy of Lewy body disease from constipation symptoms
|
|
CA3197228A1
(en)
|
2013-12-31 |
2015-07-09 |
Proteonic Biotechnology Ip B.V. |
Construct and sequence for enhanced gene expression
|
|
CA2938933A1
(en)
|
2014-03-12 |
2015-09-17 |
Prothena Biosciences Limited |
Anti-laminin4 antibodies specific for lg4-5
|
|
KR20160131082A
(ko)
|
2014-03-12 |
2016-11-15 |
프로테나 바이오사이언시즈 리미티드 |
Lg1-3에 특이적인 항-라미닌4 항체
|
|
TW201623331A
(zh)
|
2014-03-12 |
2016-07-01 |
普羅帝納生物科學公司 |
抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
|
|
ES2744526T3
(es)
|
2014-03-12 |
2020-02-25 |
Prothena Biosciences Ltd |
Anticuerpos anti-MCAM y métodos de uso asociados
|
|
WO2015155694A1
(en)
|
2014-04-08 |
2015-10-15 |
Prothena Biosciences Limited |
Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
|
|
CN107438623B
(zh)
|
2014-12-10 |
2023-07-14 |
Opko生物科学有限公司 |
长效的ctp修饰的生长激素多肽的制备方法
|
|
TWI718122B
(zh)
|
2015-01-28 |
2021-02-11 |
愛爾蘭商普羅佘納生物科技有限公司 |
抗甲狀腺素運送蛋白抗體
|
|
TWI769570B
(zh)
|
2015-01-28 |
2022-07-01 |
愛爾蘭商普羅佘納生物科技有限公司 |
抗甲狀腺素運送蛋白抗體
|
|
TWI718121B
(zh)
|
2015-01-28 |
2021-02-11 |
愛爾蘭商普羅佘納生物科技有限公司 |
抗甲狀腺素運送蛋白抗體
|
|
JP6983073B2
(ja)
|
2015-05-18 |
2021-12-17 |
ザイムトロニクス インコーポレイテッド |
磁気固定化殺菌性酵素
|
|
EP3323166B1
(en)
|
2015-07-15 |
2024-03-13 |
ZYMtronix, Inc. |
Automated bionanocatalyst production
|
|
WO2017046776A2
(en)
|
2015-09-16 |
2017-03-23 |
Prothena Biosciences Limited |
Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
|
|
WO2017046774A2
(en)
|
2015-09-16 |
2017-03-23 |
Prothena Biosciences Limited |
Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
|
|
WO2017149513A1
(en)
|
2016-03-03 |
2017-09-08 |
Prothena Biosciences Limited |
Anti-mcam antibodies and associated methods of use
|
|
WO2017153953A1
(en)
|
2016-03-09 |
2017-09-14 |
Prothena Biosciences Limited |
Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
|
|
WO2017153955A1
(en)
|
2016-03-09 |
2017-09-14 |
Prothena Biosciences Limited |
Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
|
|
CN109219615B
(zh)
|
2016-05-02 |
2022-12-09 |
普罗塞纳生物科学有限公司 |
识别tau的抗体
|
|
EP3452509A1
(en)
|
2016-05-02 |
2019-03-13 |
Prothena Biosciences Limited |
Antibodies recognizing tau
|
|
PL3452507T3
(pl)
|
2016-05-02 |
2023-01-09 |
Prothena Biosciences Limited |
Immunoterapia tau
|
|
WO2017208210A1
(en)
|
2016-06-03 |
2017-12-07 |
Prothena Biosciences Limited |
Anti-mcam antibodies and associated methods of use
|
|
WO2018007923A2
(en)
|
2016-07-02 |
2018-01-11 |
Prothena Biosciences Limited |
Anti-transthyretin antibodies
|
|
EP3478716A2
(en)
|
2016-07-02 |
2019-05-08 |
Prothena Biosciences Limited |
Anti-transthyretin antibodies
|
|
EP3478714A2
(en)
|
2016-07-02 |
2019-05-08 |
Prothena Biosciences Limited |
Anti-transthyretin antibodies
|
|
TW202444744A
(zh)
|
2016-07-11 |
2024-11-16 |
以色列商歐科生物製品有限公司 |
長效型凝血因子及其生產方法
|
|
CN109788762B
(zh)
|
2016-08-13 |
2023-07-11 |
齐姆特罗尼克斯催化系统股份有限公司 |
磁性固定化的杀生物酶和杀生物化学品
|
|
MX2019008413A
(es)
|
2017-01-13 |
2019-09-13 |
Univ California |
Celulas pluripotentes inmunodiseñadas.
|
|
CN110881274B
(zh)
|
2017-05-02 |
2024-11-15 |
普罗塞纳生物科学有限公司 |
识别tau的抗体
|
|
JP2021502955A
(ja)
|
2017-09-28 |
2021-02-04 |
プロセナ・バイオサイエンシズ・リミテッド |
シヌクレイン病の治療のための投与レジメン
|
|
JP7292569B2
(ja)
|
2017-10-06 |
2023-06-19 |
ノボ ノルディスク エー／エス |
トランスサイレチンを検出する方法
|
|
PE20211453A1
(es)
|
2017-11-29 |
2021-08-05 |
Prothena Biosciences Ltd |
Formulacion liofilizada de un anticuerpo monoclonal contra transtirretina
|
|
CN112805091A
(zh)
|
2018-09-05 |
2021-05-14 |
齐姆特罗尼克斯催化系统股份有限公司 |
在磁性支架上固定化的酶和微粒体
|
|
WO2020097561A1
(en)
|
2018-11-08 |
2020-05-14 |
Prothena Biosciences Limited |
Antibodies recognizing tau
|
|
CR20210272A
(es)
|
2018-11-26 |
2021-07-14 |
Forty Seven Inc |
Anticuerpos humanizados contra c-kit
|
|
AU2020231366A1
(en)
|
2019-03-03 |
2021-08-12 |
Prothena Biosciences Limited |
Antibodies recognizing tau
|
|
US11162079B2
(en)
|
2019-05-10 |
2021-11-02 |
The Regents Of The University Of California |
Blood type O Rh-hypo-immunogenic pluripotent cells
|
|
SG11202112506SA
(en)
|
2019-05-10 |
2021-12-30 |
Univ California |
Modified pluripotent cells
|
|
AU2020307550A1
(en)
|
2019-06-26 |
2022-02-03 |
The Regents Of The University Of California |
SIRPalpha-silenced natural killer (NK) cells
|
|
JP2022543112A
(ja)
|
2019-08-01 |
2022-10-07 |
サナ バイオテクノロジー，インコーポレイテッド |
Ｄｕｘ４発現細胞およびそれらの使用
|
|
EP4017508A1
(en)
|
2019-08-23 |
2022-06-29 |
Sana Biotechnology, Inc. |
Cd24 expressing cells and uses thereof
|
|
CA3164591A1
(en)
|
2020-01-13 |
2021-07-22 |
William Dowdle |
Modification of blood type antigens
|
|
US20230058557A1
(en)
|
2020-01-15 |
2023-02-23 |
The Regents Of The University Of California |
Transplanted cell protection via inhibition of polymorphonuclear cells
|
|
KR20220142433A
(ko)
|
2020-01-17 |
2022-10-21 |
사나 바이오테크놀로지, 인크. |
유전자 발현 조절용 안전 스위치
|
|
MX2022011831A
(es)
|
2020-03-25 |
2023-01-04 |
Sana Biotechnology Inc |
Células neurales hipoinmunogénicas para el tratamiento de trastornos y afecciones neurológicas.
|
|
CA3183994A1
(en)
|
2020-06-24 |
2021-12-30 |
Philip James Dolan Iii |
Antibodies recognizing sortilin
|
|
MX2023001831A
(es)
|
2020-08-13 |
2023-06-29 |
Sana Biotechnology Inc |
Métodos de tratamiento de pacientes sensibilizados con células hipoinmunogénicas y métodos y composiciones asociados.
|
|
KR20230137900A
(ko)
|
2020-12-31 |
2023-10-05 |
사나 바이오테크놀로지, 인크. |
Car-t 활성을 조정하기 위한 방법 및 조성물
|
|
US20240252642A1
(en)
|
2021-05-19 |
2024-08-01 |
Sana Biotechnology, Inc. |
Hypoimmunogenic rhd negative primary t cells
|
|
KR20240013135A
(ko)
|
2021-05-27 |
2024-01-30 |
사나 바이오테크놀로지, 인크. |
조작된 hla-e 또는 hla-g를 포함하는 저면역원성 세포
|
|
AU2022309875A1
(en)
|
2021-07-14 |
2024-01-25 |
Sana Biotechnology, Inc. |
Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
|
|
EP4384544A1
(en)
|
2021-08-11 |
2024-06-19 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy
|
|
EP4384598A1
(en)
|
2021-08-11 |
2024-06-19 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
|
|
AU2022325232A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified primary cells for allogeneic cell therapy
|
|
WO2023019225A2
(en)
|
2021-08-11 |
2023-02-16 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
|
|
KR20240155390A
(ko)
|
2022-02-17 |
2024-10-28 |
사나 바이오테크놀로지, 인크. |
조작된 cd47 단백질 및 이의 용도
|
|
US20250101382A1
(en)
|
2022-03-11 |
2025-03-27 |
Sana Biotechnology, Inc. |
Genetically modified cells and compositions and uses thereof
|
|
WO2023183313A1
(en)
|
2022-03-22 |
2023-09-28 |
Sana Biotechnology, Inc. |
Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
|
|
EP4634388A1
(en)
|
2022-12-14 |
2025-10-22 |
Providence Therapeutics Holdings Inc. |
Compositions and methods for infectious diseases
|
|
WO2024151541A1
(en)
|
2023-01-09 |
2024-07-18 |
Sana Biotechnology, Inc. |
Type-1 diabetes autoimmune mouse
|
|
AU2024264889A1
(en)
|
2023-05-03 |
2025-11-13 |
Sana Biotechnology, Inc. |
Methods of dosing and administration of engineered islet cells
|
|
WO2024243236A2
(en)
|
2023-05-22 |
2024-11-28 |
Sana Biotechnology, Inc. |
Methods of delivery of islet cells and related methods
|
|
WO2025043172A1
(en)
|
2023-08-23 |
2025-02-27 |
Sana Biotechnology, Inc. |
Modified cd47 proteins and their uses
|
|
AR133834A1
(es)
|
2023-09-15 |
2025-11-05 |
Prothena Biosciences Ltd |
Agentes de penetración célular y sus usos
|
|
TW202530246A
(zh)
|
2023-09-15 |
2025-08-01 |
愛爾蘭商歐賽爾普羅希那有限公司 |
細胞穿透劑及其用途
|
|
WO2025059486A1
(en)
|
2023-09-15 |
2025-03-20 |
Prothena Biosciences Limited |
Anti-tdp-43 antibodies and uses thereof
|
|
AR133830A1
(es)
|
2023-09-15 |
2025-11-05 |
Prothena Platform Tech Limited |
Métodos, composiciones y kits que incluyen agentes de penetración celular
|
|
WO2025166633A2
(en)
|
2024-02-07 |
2025-08-14 |
Westlake Genetech. Ltd. |
Split gene editing systems and uses thereof
|